NATCO Pharma Invests USD 8 Million in eGenesis, a Biotechnology Company
NATCO Pharma Limited, a Hyderabad-based pharmaceutical company, has announced that its Canadian subsidiary, NATCO Pharma (Canada) Inc., has invested USD 8 million in eGenesis, Inc., a biotechnology company at the forefront of xenotransplantation. eGenesis is developing safe and effective human-compatible organs for transplant, with a focus on eliminating waitlist mortality and transforming the treatment of organ failure. The investment will support eGenesis' research and development efforts in kidney transplant, acute liver failure, and heart transplant. The eGenesis Genome Engineering and Production (EGEN™) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering.
Key Highlights
- NATCO Pharma Limited invests USD 8 million in eGenesis, Inc., a biotechnology company specializing in xenotransplantation.
- eGenesis is developing human-compatible organs for transplant, aiming to end the global transplant shortage and transform organ failure treatment.
- The investment will support eGenesis' research and development in kidney transplant, acute liver failure, and heart transplant.
- eGenesis' Genome Engineering and Production (EGEN™) Platform is a unique technology addressing cross-species molecular incompatibilities and viral risk via genetic engineering.
- NATCO Pharma's support will contribute to bringing eGenesis' innovative therapies to market.